209 related articles for article (PubMed ID: 36048866)
1. Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.
Harlow CE; Patel VV; Waterworth DM; Wood AR; Beaumont RN; Ruth KS; Tyrrell J; Oguro-Ando A; Chu AY; Frayling TM
Hum Mol Genet; 2023 Jan; 32(3):496-505. PubMed ID: 36048866
[TBL] [Abstract][Full Text] [Related]
2. Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study.
Levin MG; Klarin D; Assimes TL; Freiberg MS; Ingelsson E; Lynch J; Natarajan P; O'Donnell C; Rader DJ; Tsao PS; Chang KM; Voight BF; Damrauer SM;
JAMA Netw Open; 2021 Jan; 4(1):e2034461. PubMed ID: 33464320
[TBL] [Abstract][Full Text] [Related]
3. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.
Yarmolinsky J; Díez-Obrero V; Richardson TG; Pigeyre M; Sjaarda J; Paré G; Walker VM; Vincent EE; Tan VY; Obón-Santacana M; Albanes D; Hampe J; Gsur A; Hampel H; Pai RK; Jenkins M; Gallinger S; Casey G; Zheng W; Amos CI; ; ; ; Smith GD; Martin RM; Moreno V
PLoS Med; 2022 Feb; 19(2):e1003897. PubMed ID: 35113855
[TBL] [Abstract][Full Text] [Related]
4. Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study.
Yuan S; Burgess S; Laffan M; Mason AM; Dichgans M; Gill D; Larsson SC
J Am Heart Assoc; 2021 Apr; 10(8):e019644. PubMed ID: 33834859
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study.
Li X; Meng X; He Y; Spiliopoulou A; Timofeeva M; Wei WQ; Gifford A; Yang T; Varley T; Tzoulaki I; Joshi P; Denny JC; Mckeigue P; Campbell H; Theodoratou E
PLoS Med; 2019 Oct; 16(10):e1002937. PubMed ID: 31626644
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis.
Wang K; Shi M; Huang C; Fan B; Luk AOY; Kong APS; Ma RCW; Chan JCN; Chow E
Cardiovasc Diabetol; 2022 Sep; 21(1):192. PubMed ID: 36151532
[TBL] [Abstract][Full Text] [Related]
7. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.
Harlow CE; Gandawijaya J; Bamford RA; Martin ER; Wood AR; van der Most PJ; Tanaka T; Leonard HL; Etheridge AS; Innocenti F; Beaumont RN; Tyrrell J; Nalls MA; Simonsick EM; Garimella PS; Shiroma EJ; Verweij N; van der Meer P; Gansevoort RT; Snieder H; Gallins PJ; Jima DD; Wright F; Zhou YH; Ferrucci L; Bandinelli S; Hernandez DG; van der Harst P; Patel VV; Waterworth DM; Chu AY; Oguro-Ando A; Frayling TM
Am J Hum Genet; 2022 Sep; 109(9):1638-1652. PubMed ID: 36055212
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study.
Li GH; Cheung CL; Chung AK; Cheung BM; Wong IC; Fok MLY; Au PC; Sham PC
Psychol Med; 2022 Jul; 52(9):1765-1776. PubMed ID: 33032663
[TBL] [Abstract][Full Text] [Related]
9. The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.
Gill D; Zagkos L; Gill R; Benzing T; Jordan J; Birkenfeld AL; Burgess S; Zahn G
BMC Med; 2023 Dec; 21(1):504. PubMed ID: 38110950
[TBL] [Abstract][Full Text] [Related]
10. Genetically Determined Levels of Circulating Cytokines and Risk of Stroke.
Georgakis MK; Gill D; Rannikmäe K; Traylor M; Anderson CD; Lee JM; Kamatani Y; Hopewell JC; Worrall BB; Bernhagen J; Sudlow CLM; Malik R; Dichgans M
Circulation; 2019 Jan; 139(2):256-268. PubMed ID: 30586705
[TBL] [Abstract][Full Text] [Related]
11. A data-driven approach for studying the role of body mass in multiple diseases: a phenome-wide registry-based case-control study in the UK Biobank.
Hyppönen E; Mulugeta A; Zhou A; Santhanakrishnan VK
Lancet Digit Health; 2019 Jul; 1(3):e116-e126. PubMed ID: 33323262
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study.
Rosoff DB; Davey Smith G; Mehta N; Clarke TK; Lohoff FW
PLoS Med; 2020 Dec; 17(12):e1003410. PubMed ID: 33275596
[TBL] [Abstract][Full Text] [Related]
13. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.
De Marchis GM; Dittrich TD; Malik R; Zietz AV; Kriemler LF; Ference BA; Dichgans M; Georgakis MK
Atherosclerosis; 2022 Nov; 361():41-46. PubMed ID: 36244797
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of genetically proxied interleukin-5 inhibition: A mendelian randomization study.
Alton P; Hughes DM; Zhao SS
Respir Investig; 2023 Mar; 61(2):149-152. PubMed ID: 36682083
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Glycated Hemoglobin (HbA
Au Yeung SL; Luo S; Schooling CM
Diabetes Care; 2018 Sep; 41(9):1991-1997. PubMed ID: 29950300
[TBL] [Abstract][Full Text] [Related]
16. Genetically Determined Platelet Count and Risk of Cardiovascular Disease.
Gill D; Monori G; Georgakis MK; Tzoulaki I; Laffan M
Arterioscler Thromb Vasc Biol; 2018 Dec; 38(12):2862-2869. PubMed ID: 30571169
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Traits and Stroke Risk in Individuals of African Ancestry: Mendelian Randomization Analysis.
Fatumo S; Karhunen V; Chikowore T; Sounkou T; Udosen B; Ezenwa C; Nakabuye M; Soremekun O; Daghlas I; Ryan DK; Taylor A; Mason AM; Damrauer SM; Vujkovic M; Keene KL; Fornage M; Järvelin MR; Burgess S; Gill D
Stroke; 2021 Aug; 52(8):2680-2684. PubMed ID: 34078102
[TBL] [Abstract][Full Text] [Related]
18. Genetic Liability to Depression and Risk of Coronary Artery Disease, Myocardial Infarction, and Other Cardiovascular Outcomes.
Lu Y; Wang Z; Georgakis MK; Lin H; Zheng L
J Am Heart Assoc; 2021 Jan; 10(1):e017986. PubMed ID: 33372528
[TBL] [Abstract][Full Text] [Related]
19. Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
Larsson SC; Burgess S; Michaëlsson K
JAMA; 2017 Jul; 318(4):371-380. PubMed ID: 28742912
[TBL] [Abstract][Full Text] [Related]
20. Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.
Yuan S; Wang L; Zhang H; Xu F; Zhou X; Yu L; Sun J; Chen J; Ying H; Xu X; Yu Y; Spiliopoulou A; Shen X; Wilson J; Gill D; Theodoratou E; Larsson SC; Li X
EBioMedicine; 2023 Mar; 89():104488. PubMed ID: 36842216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
